+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Cancer Immunotherapy Market by Product (Cell Therapies, Checkpoint Inhibitors, Immunomodulators), Function (Breast Cancer, Colorectal Cancer, Head & Neck Cancer), End-User - Forecast 2024-2030- Product Image
Global Cancer Immunotherapy Market by Product (Cell Therapies, Checkpoint Inhibitors, Immunomodulators), Function (Breast Cancer, Colorectal Cancer, Head & Neck Cancer), End-User - Forecast 2024-2030- Product Image
Sale

Global Cancer Immunotherapy Market by Product (Cell Therapies, Checkpoint Inhibitors, Immunomodulators), Function (Breast Cancer, Colorectal Cancer, Head & Neck Cancer), End-User - Forecast 2024-2030

  • PDF Icon

    Report

  • 195 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5337548
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cancer Immunotherapy Market size was estimated at USD 73.38 billion in 2023, USD 77.39 billion in 2024, and is expected to grow at a CAGR of 5.54% to reach USD 107.11 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer Immunotherapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer Immunotherapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer Immunotherapy Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AstraZeneca PLC, Avid Bioservices, Inc., Bayer AG, Bristol-Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, ELI Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GSK PLC, Janssen Global Services, LLC, Merck & Co., Inc., Novartis International AG, OSE Immunotherapeutics SA, and Pfizer, Inc.

Market Segmentation & Coverage

This research report categorizes the Cancer Immunotherapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Cell Therapies
      • Chimeric Antigen Receptor T Cell Therapy
      • Dendritic Cells
    • Checkpoint Inhibitors
      • Cytotoxic T-Lymphocyte-Associated Protein-4
      • Programmed Death 1 & Programmed Death Ligand 1
    • Immunomodulators
      • Granulocyte-Macrophage Colony-Stimulating Factor
      • Interferons
      • Interleukins
      • Oncolytic Virus
    • Monoclonal Antibodies
      • Bispecific Monoclonal Antibodies
      • Conjugated Monoclonal Antibodies
      • Naked Monoclonal Antibodies
    • Vaccines
      • Prophylactic Vaccines
      • Therapeutic Vaccines
  • Function
    • Breast Cancer
    • Colorectal Cancer
    • Head & Neck Cancer
    • Lung Cancer
    • Melanoma
    • Multiple Myeloma
    • Prostate Cancer
  • End-User
    • Cancer Research Institutes
    • Clinics
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Cancer Immunotherapy Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer Immunotherapy Market?
  3. What are the technology trends and regulatory frameworks in the Cancer Immunotherapy Market?
  4. What is the market share of the leading vendors in the Cancer Immunotherapy Market?
  5. Which modes and strategic moves are suitable for entering the Cancer Immunotherapy Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cancer Immunotherapy Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cancer patients worldwide
5.1.1.2. Increasing adoption of advanced cancer therapeutics
5.1.1.3. Surging investments in research and development activities of cancer treatment
5.1.2. Restraints
5.1.2.1. Capital intensive treatment and procedures
5.1.3. Opportunities
5.1.3.1. Extensive development of bioinformatics tools in drug development process
5.1.3.2. Growing number of clinical trials for cancer immunotherapy
5.1.4. Challenges
5.1.4.1. Complications in cancer limiting the immune response
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Cancer Immunotherapy Market, by Product
6.1. Introduction
6.2. Cell Therapies
6.3.1. Chimeric Antigen Receptor T Cell Therapy
6.3.2. Dendritic Cells
6.3. Checkpoint Inhibitors
6.4.1. Cytotoxic T-Lymphocyte-Associated Protein-4
6.4.2. Programmed Death 1 & Programmed Death Ligand 1
6.4. Immunomodulators
6.5.1. Granulocyte-Macrophage Colony-Stimulating Factor
6.5.2. Interferons
6.5.3. Interleukins
6.5.4. Oncolytic Virus
6.5. Monoclonal Antibodies
6.6.1. Bispecific Monoclonal Antibodies
6.6.2. Conjugated Monoclonal Antibodies
6.6.3. Naked Monoclonal Antibodies
6.6. Vaccines
6.7.1. Prophylactic Vaccines
6.7.2. Therapeutic Vaccines
7. Cancer Immunotherapy Market, by Function
7.1. Introduction
7.2. Breast Cancer
7.3. Colorectal Cancer
7.4. Head & Neck Cancer
7.5. Lung Cancer
7.6. Melanoma
7.7. Multiple Myeloma
7.8. Prostate Cancer
8. Cancer Immunotherapy Market, by End-User
8.1. Introduction
8.2. Cancer Research Institutes
8.3. Clinics
8.4. Hospitals
9. Americas Cancer Immunotherapy Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Cancer Immunotherapy Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Cancer Immunotherapy Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Amgen Inc.
13.1.2. AstraZeneca PLC
13.1.3. Avid Bioservices, Inc.
13.1.4. Bayer AG
13.1.5. Bristol-Myers Squibb
13.1.6. C.H. Boehringer Sohn AG & Ko. KG
13.1.7. ELI Lilly and Company
13.1.8. F. Hoffmann-La Roche Ltd
13.1.9. Gilead Sciences, Inc.
13.1.10. GSK PLC
13.1.11. Janssen Global Services, LLC
13.1.12. Merck & Co., Inc.
13.1.13. Novartis International AG
13.1.14. OSE Immunotherapeutics SA
13.1.15. Pfizer, Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. CANCER IMMUNOTHERAPY MARKET RESEARCH PROCESS
FIGURE 2. CANCER IMMUNOTHERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CANCER IMMUNOTHERAPY MARKET DYNAMICS
FIGURE 7. CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
FIGURE 10. CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. CANCER IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. CANCER IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 6. CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 8. CANCER IMMUNOTHERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. CANCER IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 12. CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. CANCER IMMUNOTHERAPY MARKET SIZE, BY PROGRAMMED DEATH 1 & PROGRAMMED DEATH LIGAND 1, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 16. CANCER IMMUNOTHERAPY MARKET SIZE, BY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. CANCER IMMUNOTHERAPY MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. CANCER IMMUNOTHERAPY MARKET SIZE, BY INTERLEUKINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 22. CANCER IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. CANCER IMMUNOTHERAPY MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. CANCER IMMUNOTHERAPY MARKET SIZE, BY NAKED MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 27. CANCER IMMUNOTHERAPY MARKET SIZE, BY PROPHYLACTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 30. CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. CANCER IMMUNOTHERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. CANCER IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. CANCER IMMUNOTHERAPY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 67. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 68. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 69. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 70. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 71. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 72. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 73. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 75. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 76. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 77. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 79. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 80. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 81. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 94. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 100. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 101. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 102. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 103. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 104. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 105. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 106. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 107. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 109. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 110. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 111. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 112. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 113. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 114. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 115. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 116. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 117. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 118. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 119. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 120. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 121. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 122. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 123. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 125. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 126. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 127. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 128. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 129. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 130. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 131. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 133. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 134. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 135. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 136. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 137. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 138. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 139. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 141. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 142. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 143. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 144. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 145. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 146. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 147. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 149. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 150. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 151. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 152. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 153. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 154. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 155. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 156. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 157. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 158. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 159. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 160. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 161. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 162. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 163. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 165. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 166. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 167. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 168. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 169. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 170. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 171. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 172. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 173. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 174. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 175. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 176. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 177. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 178. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 179. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 181. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 182. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 183. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 184. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 185. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 186. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 187. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 188. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 189. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 190. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 191. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 192. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 193. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 194. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 195. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 205. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 206. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 207. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 208. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 209. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 210. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 211. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 212. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 213. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 214. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 215. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 217. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 218. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 219. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 220. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 222. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 223. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 224. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 225. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 226. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 227. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 228. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 230. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 231. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 232. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 233. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 234. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 235. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 236. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 237. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 238. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 239. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 240. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 241. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 242. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 243. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 244. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 247. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 248. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 249. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 250. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 251. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 252. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 253. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 254. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 255. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 256. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 257. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 258. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 259. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 260. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 272. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 273. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 274. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 275. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 276. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 277. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 278. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 279. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 280. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 281. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 282. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 283. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 284. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 285. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 286. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 287. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 288. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 289. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 290. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 291. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 292. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 293. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 294. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 295. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 296. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 297. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 298. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 299. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 300. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 301. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 302. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 303. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 304. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 305. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 306. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 307. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 308. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 310. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 312. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 314. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 316. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 318. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 320. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 322. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 324. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 325. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 326. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 327. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 328. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 329. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 330. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 331. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 332. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 333. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 334. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
TABLE 335. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 336. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 337. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 338. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 339. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 340. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 341. SWITZERLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 342. SWITZERLAND CANCER IMMUNOTHERAPY MARKE

Companies Mentioned

  • Amgen Inc.
  • AstraZeneca PLC
  • Avid Bioservices, Inc.
  • Bayer AG
  • Bristol-Myers Squibb
  • C.H. Boehringer Sohn AG & Ko. KG
  • ELI Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GSK PLC
  • Janssen Global Services, LLC
  • Merck & Co., Inc.
  • Novartis International AG
  • OSE Immunotherapeutics SA
  • Pfizer, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages195
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 77.39 Billion
Forecasted Market Value ( USD ) by 2030 $ 107.11 Billion
Compound Annual Growth Rate5.5%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Global Cancer Immunotherapy Drugs Market by Type (Cancer Vaccines, Checkpoint Inhibitors, Immunomodulators), Indication (Breast Cancer, Colorectal Cancer, Head & Neck Cancer), End-user - Forecast 2024-2030 - Product Image

Global Cancer Immunotherapy Drugs Market by Type (Cancer Vaccines, Checkpoint Inhibitors, Immunomodulators), Indication (Breast Cancer, Colorectal Cancer, Head & Neck Cancer), End-user - Forecast 2024-2030

  • Report
  • 188 Pages
  • Global
From
Cancer Immunotherapy Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Drug Type (Monoclonal antibodies, Immunomodulators), By Cancer Type (Lung, Breast), By Service Type, By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Cancer Immunotherapy Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Drug Type (Monoclonal antibodies, Immunomodulators), By Cancer Type (Lung, Breast), By Service Type, By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 98 Pages
  • Global
From
Global Immunotherapy Drugs Market by Type (Cancer Vaccines, Checkpoint Inhibitors, Cytokines-Based Therapy), Application (Autoimmune Disease, Infectious Disease, Neurology), End-User - Forecast 2024-2030 - Product Image

Global Immunotherapy Drugs Market by Type (Cancer Vaccines, Checkpoint Inhibitors, Cytokines-Based Therapy), Application (Autoimmune Disease, Infectious Disease, Neurology), End-User - Forecast 2024-2030

  • Report
  • 191 Pages
  • Global
From
Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics),Regional Outlook- Global Forecast up to 2030 - Product Image

Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics),Regional Outlook- Global Forecast up to 2030

  • Report
  • 116 Pages
  • Global
From
Global Cancer Immunotherapy Market Size, Share & Trends Analysis Report, Product, Application, Distribution (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End Use, Region, and Segment Forecasts, 2024-2030 - Product Image

Global Cancer Immunotherapy Market Size, Share & Trends Analysis Report, Product, Application, Distribution (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End Use, Region, and Segment Forecasts, 2024-2030

  • Report
  • 110 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.